Search results for "Carcinogen"

showing 10 items of 6867 documents

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus

2021

Summary There are no internationally recognized criteria available to determine preparedness for hospital discharge after esophagectomy. This study aims to achieve international consensus using Delphi methodology. The expert panel consisted of 40 esophageal surgeons spanning 16 countries and 4 continents. During a 3-round, web-based Delphi process, experts voted for discharge criteria using 5-point Likert scales. Data were analyzed using descriptive statistics. Consensus was reached if agreement was ≥75% in round 3. Consensus was achieved for the following basic criteria: nutritional requirements are met by oral intake of at least liquids with optional supplementary nutrition via jejunal fe…

medicine.medical_specialtydischarge criteriaConsensusDelphi Techniquemedicine.medical_treatmentDelphi methodVital signs03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterSurveys and QuestionnairesmedicineHumansFeeding tubecomputer.programming_languageHospital stayDescriptive statisticsddc:617business.industryGastroenterologyGeneral Medicinemedicine.diseaseColorectal surgeryDischarge criteriahospital stayPatient Discharge3. Good healthEsophagectomyDelphi consensusEsophagectomy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyMedical emergencyOutcomes researchbusinesscomputerDelphi
researchProduct

Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option

2020

Nowadays, the best treatment option for ovarian cancer recurrence is often subjective, can vary in the different centers and depend on personal experience. Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)-DESKTOP studies have identified a population of patients who could benefit from secondary surgery. The results of the Gynecologic Oncology Group (GOG)-0213 study were recently published, which showed no advantage in terms of overall survival (OS) in patients with platinum-sensitive recurrent epithelial ovarian undergoing secondary cytoreductive surgery (SCS) compared to chemotherapy alone. Aim of this narrative review is to summarize the best aspects that can make ovarian cancer recurre…

medicine.medical_specialtyeducation.field_of_studyChemotherapyendocrine system diseasesPerformance statusbusiness.industrymedicine.medical_treatmentPopulationTreatment optionsGynecologic oncologymedicine.diseaseSurgery03 medical and health sciences0302 clinical medicineRecurrent Ovarian Cancer030220 oncology & carcinogenesismedicineSurgery030212 general & internal medicineOvarian cancereducationbusinessContraindicationGland Surgery
researchProduct

Atteinte de la Muscularis Mucosae dans les tumeurs urothéliales T1 de vessie : facteur pronostique de progression après immunothérapie par BCG

2012

OBJECTIVES: To study the prognostic impact of muscularis mucosae (MM) invasion for pT1 bladder cancer treated by transurethral resection (TUR) and adjuvant Bacille Calmette-Guerin (BCG) intravesical immunotherapy. METHODS: Sixty-six patients treated by BCG intravesical instillations were substaged into pT1a and pT1b, regarding Muscularis Mucosae invasion. Tumor grade, associated carcinoma in situ (CIS), multifocality, tumoral size up to 3cm, BCG maintenance were noted. With a mean follow-up of 50.5±38 months, we studied recurrence, progression, overall and specific survival. Cox's model method was used for multivariate analysis. RESULTS: Tumor recurrence was observed in 30±7% and 43±10% (P=…

medicine.medical_specialtyeducation.field_of_studyPathologyMuscularis mucosaeBladder cancerbusiness.industryUrologymedicine.medical_treatmentCarcinoma in situPopulation030232 urology & nephrologyImmunotherapymedicine.diseaseGastroenterology3. Good healthCystectomy03 medical and health sciences0302 clinical medicineTumor progression030220 oncology & carcinogenesisInternal medicinemedicineProgression-free survivaleducationbusinessProgrès en Urologie
researchProduct

The evolution of European Medicines Agency drug approval: the adaptive licensing: Table 1

2015

In March 2014, the European Medicines Agency (EMA) launched a pilot project of ‘adaptive licensing’ to speed up access to drugs in development, in order to respond to unmet medical needs. The project will involve parallel scientific advice from the regulatory agency, pharmaceutical industry, the companies Health Technology Assessment (HTAs) bodies, organisations studying guidelines on clinical treatment and patient associations. The traditional process of drug authorisation is divided into several parts, involving in vitro studies and in vivo studies in animals (preclinical studies), as well as phase 1–3 randomised controlled trials conducted in humans over a predefined period. When authori…

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationHealth technology030226 pharmacology & pharmacyClinical pharmacyTransplantation03 medical and health sciences0302 clinical medicineNursing030220 oncology & carcinogenesisFamily medicinePharmacovigilanceMedicineObservational studyGeneral Pharmacology Toxicology and PharmaceuticsbusinesseducationAdverse effectPharmaceutical industryEuropean Journal of Hospital Pharmacy
researchProduct

Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance

2019

OBJECTIVES To determine the rate of Gleason Grade Group (GGG) upgrading in African-American (AA) men with a prior diagnosis of low-grade prostate cancer (GGG 1 or GGG 2) on 12-core systematic biopsy (SB) after multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy (FB); and whether AA men who continued active surveillance (AS) after mpMRI and FB fared differently than a predominantly Caucasian (non-AA) population. PATIENTS AND METHODS A database of men who had undergone mpMRI and FB was queried to determine rates of upgrading by FB amongst men deemed to be AS candidates based on SB prior to referral. After FB, Kaplan-Meier curves were generated for AA men and non-AA men who th…

medicine.medical_specialtyeducation.field_of_studybusiness.industryUrologyPopulation030232 urology & nephrologyUrologyGleason grademedicine.disease03 medical and health sciencesProstate cancer0302 clinical medicineInterquartile range030220 oncology & carcinogenesisMedicineAfrican american menbusinesseducationSystematic biopsyFusion BiopsyMultiparametric Magnetic Resonance ImagingBJU International
researchProduct

Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus.

2021

Abstract Objective Type 2 Diabetes (T2D) is a major risk factor for the development and progression of non-alcoholic fatty liver disease (NAFLD). The published prevelance in epidemiological studies in this high risk population exceeds 70%. The aim of this analysis was to investigate the impact of NAFLD on T2D patients in Germany. Methods Using the Disease Analyzer Database (IQVIA), T2D patients with NAFLD diagnosed in Germany were matched to a cohort without NAFLD controlling for age, sex, physician, index year and metabolic comorbidities and assessed for their risk of developing myocardial infarction, stroke, peripheral arterial disease (PAD) or chronic kidney disease, as well as the type …

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismPopulationType 2 diabetesComorbidity03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansInsulinRisk factoreducationeducation.field_of_studybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseasedigestive system diseasesDiabetes Mellitus Type 2030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessKidney diseaseExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study

2017

Background: The measurement of TSH receptor (TSHR) antibodies is warranted for diagnosis of Graves’ disease (GD). Objective: The performance, detection sensitivity, and specificity of 6 TSHR immunoassays were compared. Methods: Two bioassays and 4 binding assays (Kronus, Immulite, Kryptor, Dynex) were compared in a dilution study performed in patients with autoimmune thyroid disease. Both bioassays were compared to 2 binding assays using stimulatory (M22) and blocking (K1–70) monoclonal antibody (MAb) mixtures. Results: Thirty samples from stimulatory (TSAb)-positive/blocking (TBAb)-negative patients with GD were diluted serially and measured in all assays. Samples were positive until dilut…

medicine.medical_specialtyendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismMonoclonal antibodyThyroiditis03 medical and health sciences0302 clinical medicineInternal medicinemedicineBioassaySample dilutionReceptorTranslational Thyroidology / Original Paperbiologybusiness.industrymedicine.diseaseMolecular biologyAnti-thyroid autoantibodiesEndocrinologyMulticenter study030220 oncology & carcinogenesisbiology.proteinAntibodybusinessEuropean Thyroid Journal
researchProduct

Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome

2014

Resistin is an adipocyte- and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the…

medicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInflammationType 2 diabetesModels BiologicalType 2 diabetemetabolic syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceAdipocyteInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansResistin030304 developmental biologyMetabolic SyndromePharmacology0303 health sciencesbusiness.industryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Insulinnutritional and metabolic diseasesCardiovascular diseasemedicine.disease3. Good healthcardiovascular diseasesEndocrinologyDiabetes Mellitus Type 2chemistryCardiovascular Diseases030220 oncology & carcinogenesisImmunologyResistintype 2 diabetesInflammation MediatorsMetabolic syndromemedicine.symptombusinesshormones hormone substitutes and hormone antagonists
researchProduct

Thyrotropin Receptor Blocking Antibodies.

2018

AbstractAutoantibodies (Ab) against the thyroid-stimulating hormone receptor (TSHR) are frequently found in autoimmune thyroid disease (AITD). Autoantibodies to the TSHR (anti-TSHR-Ab) may mimic or block the action of TSH or be functionally neutral. Measurement of anti-TSHR-Ab can be done either via competitive-binding immunoassays or with functional cell-based bioassays. Antibody-binding assays do not assess anti-TSHR-Ab functionality, but rather measure the concentration of total anti-TSHR binding activity. In contrast, functional cell-based bioassays indicate whether anti-TSHR-Ab have stimulatory or blocking activity. Historically bioassays for anti-TSHR-Ab were research tools and were u…

medicine.medical_specialtyendocrine systemendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismHashimoto DiseaseReviewBiochemistryThyroiditisThyrotropin receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineBlocking antibodymedicineAnimalsHumansReceptorAntibodies BlockingAutoantibodiesbinding assaycell-based bioassaybiologybusiness.industryBiochemistry (medical)AutoantibodyReceptors ThyrotropinGeneral MedicineHashimoto’s thyroiditismedicine.diseaseTSH receptor blocking autoantibodieseye diseasesEndocrinologyHormone receptor030220 oncology & carcinogenesisImmunologybiology.proteinBiological AssayAntibodybusinessGraves’ diseasehormones hormone substitutes and hormone antagonistsHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Molecular endoscopic imaging: the future is bright

2019

The prediction and final survival rate of gastrointestinal cancers are dependent on the stage of disease. The ideal would be to detect those gastrointestinal lesions at early stage or even premalignant forms which are difficult to detect by conventional endoscopy with white light optical imaging as they show minimum or no changes in morphological characteristics and are thus left untreated. The introduction of molecular imaging has greatly changed the pattern for detecting gastrointestinal lesions from purely macroscopic structural imaging to the molecular level. It allows microscopic examination of the gastrointestinal mucosa with endoscopy after the topical or systemic application of mol…

medicine.medical_specialtyex vivo studyReviewAntibody labeling03 medical and health sciencesEndoscopic imagingconfocal endomicroscopy0302 clinical medicinemedicinelcsh:RC799-869Stage (cooking)endoscopySurvival rateIdeal (set theory)medicine.diagnostic_testbusiness.industryGastroenterologymolecular imagingEndoscopy030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyRadiologyMolecular imagingin vivo imagingbusinessPreclinical imagingantibody labelingTherapeutic Advances in Gastrointestinal Endoscopy
researchProduct